Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.42 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | FURIN | P09958 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY4R | P50391 | 3/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23286101 | 0.94 | FAP (0.42) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL22128021 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL22128022 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL24476142 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL32667737 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL24848129 | 0.93 | FAP (0.44) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL24224636 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL22138625 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL16946352 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R | |
| SCHEMBL23943282 | 0.93 | FAP (0.40) | FAPMAP1LC3BFURINHTTNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | FAP 70/4885MAP1LC3B 2368/4885FURIN 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.